Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.52 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391047 | 1.00 | ANPEP (0.52) | ANPEPERAP1ERAP2KEAP1CYP2A6 | |
| SCHEMBL7730597 | 1.00 | ANPEP (0.52) | ANPEPERAP1ERAP2KEAP1CYP2A6 | |
| SCHEMBL8896127 | 0.88 | GRIK1 (0.50) | ANPEPERAP1ERAP2HTR2ASMN1; SMN2 | |
| SCHEMBL8895420 | 0.88 | GRIK1 (0.50) | ANPEPERAP1ERAP2HTR2ASMN1; SMN2 | |
| SCHEMBL28174568 | 0.80 | LOXL2 (0.47) | ANPEPERAP1ERAP2LOXL2ALDH1A1 | |
| SCHEMBL28174584 | 0.80 | CYP1A2 (0.47) | CYP2A6TAAR1METAP2METAP1ALDH1A1 | |
| SCHEMBL5774965 | 0.79 | CTSC (0.48) | ANPEPERAP1ERAP2CYP2A6HTR2A | |
| SCHEMBL5758862 | 0.79 | CTSC (0.48) | ANPEPERAP1ERAP2CYP2A6HTR2A | |
| SCHEMBL10348476 | 0.79 | ANPEP (0.47) | ANPEPERAP1ERAP2CYP2A6HTR2A | |
| SCHEMBL1263137 | 0.78 | EPHX1 (0.56) | ANPEPCYP2A6TAAR1EPHX1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306053-A1 | Highly selective rho-kinase inhibitor | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2009-12-10 | — | — | US | claimed |
| EP-1878732-B1 | HIGHLY SELECTIVE Rho-KINASE INHIBITOR | WESTERN THERAPEUTICS INST INC (JP) | 2009-02-25 | — | — | EP | claimed |
| EP-1878732-A1 | HIGHLY SELECTIVE Rho-KINASE INHIBITOR | D. Western Therapeutics Institute (JP) | 2008-01-16 | — | — | EP | claimed |
| EP-1232183-B1 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LAB (US) | 2006-01-18 | — | — | EP | claimed |
| US-6777535-B1 | USEFUL FOR TREATING CONDITIONS WHICH ARISE OR ARE EXACERBATED BY ANGIOGENESIS | ABBOTT LABORATORIES | 2004-08-17 | — | — | US | claimed |
| US-6753408-B1 | DRUGS USED FOR THERAPY | ABBVIE INC. | 2004-06-22 | — | — | US | claimed |
| EP-1242455-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2002-09-25 | — | — | EP | claimed |
| EP-1232183-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2002-08-21 | — | — | EP | claimed |
| US-20020065264-A1 | Cysteine protease inhibitors containing heterocyclic leaving groups | ZIMMERMAN MARY P (US) | 2002-05-30 | — | — | US | claimed |
| US-6297277-B1 | PEPTIDYL KETONES HAVING HETEROCYCLIC LEAVING GROUPS; CATHEPSIN INHIBITORS | PROTOTEK, INC. | 2001-10-02 | — | — | US | claimed |
| US-5434248-A | Peptidyl derivatives as inhibitors of interleukin-1β converting enzyme | MERCK & CO., INC. (US) | 1995-07-18 | — | — | US | claimed |
| US-5430128-A | Peptidyl derivatives as inhibitors of interleukin-1β converting enzyme | MERCK & CO., INC. (US) | 1995-07-04 | — | — | US | claimed |
| WO-1995015749-A1 | CYSTEINE PROTEASE INHIBITORS CONTAINING HETEROCYCLIC LEAVING GROUPS | PROTOTEK, INC. (US) | 1995-06-15 | — | — | WO | claimed |
| WO-1993016710-A1 | PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | MERCK & CO., INC. (US) | 1993-09-02 | — | — | WO | claimed |
| WO-1993014777-A1 | PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | MERCK & CO., INC. (US) | 1993-08-05 | — | — | WO | claimed |
| EP-0547699-A1 | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme | MERCK & CO. INC. (US) | 1993-06-23 | — | — | EP | claimed |
| EP-0519748-A2 | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme | MERCK & CO. INC. (US) | 1992-12-23 | — | — | EP | claimed |
| EP-0417454-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1991-03-20 | — | — | EP | claimed |
| WO-1988005049-A1 | NOVEL COMPOUNDS | Aktiebolaget Hässle (SE) | 1988-07-14 | — | — | WO | claimed |
| EP-0273893-A2 | Novel compounds | Aktiebolaget Hässle (SE) | 1988-07-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306053-A1 | Highly selective rho-kinase inhibitor | ROCK1, ROCK2, RHOT2 | ANPEP 2321/4885ERAP1 1810/4885ERAP2 2398/4885 |
| US-20020065264-A1 | Cysteine protease inhibitors containing heterocyclic leaving groups | HPN, PREP, SPINT2 | ANPEP 29/4885ERAP1 61/4885ERAP2 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.